NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said on Thursday it has received €2 million ($2.4 million) in financing from funds managed by French private investment firm A Plus Finance.

The funds will go toward the continued development of genetic tests for colorectal cancer and liver cancer, Integragen, also based in France, said, and to accelerate R&D and commercialization efforts directed at molecular diagnostics for autism.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.